Last reviewed · How we verify

Vyloy — Competitive Intelligence Brief

Vyloy (ZOLBETUXIMAB) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Claudin 18.2-directed Cytolytic Antibody [EPC]. Area: Oncology.

marketed Claudin 18.2-directed Cytolytic Antibody [EPC] Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Vyloy (ZOLBETUXIMAB) — Astellas. Vyloy works by binding to Claudin 18.2 on cancer cells, triggering their destruction.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Vyloy TARGET ZOLBETUXIMAB Astellas marketed Claudin 18.2-directed Cytolytic Antibody [EPC] 2024-01-01
VYLOY ZOLBETUXIMAB-CLZB ASTELLAS marketed Claudin 18.2-directed Cytolytic Antibody [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Claudin 18.2-directed Cytolytic Antibody [EPC] class)

  1. ASTELLAS · 1 drug in this class
  2. Astellas · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vyloy — Competitive Intelligence Brief. https://druglandscape.com/ci/zolbetuximab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: